Is Egrifta (Tesamorelin) Legal in Kentucky?

Federal Legal Framework for Tesamorelin

Tesamorelin is a synthetic analogue of growth-hormone-releasing factor (GRF). The FDA approved the brand Egrifta in 2010 and a reformulated version, Egrifta SV, in 2019 under NDA 022505 for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. [1] That approval confers full federal legality as a prescription drug under 21 U.S.C. § 353.

Because Egrifta holds a specific approved indication, tesamorelin does not sit in the same gray zone as purely research-grade peptides. A prescription dispensed and filled in accordance with the approved labeling is federally lawful anywhere in the United States, including Kentucky.

Controlled Substance Classification

Tesamorelin does not appear in any schedule of the federal Controlled Substances Act (21 U.S.C. § 812). [2] The Drug Enforcement Administration has not classified it as a Schedule I through V substance, which means routine DEA registration is not required to prescribe or dispense it. Prescribers still need a valid state license and must follow standard prescription requirements under their medical practice act.

FDA Category 2 Bulks List and Compounding Restrictions

The picture changes for compounded tesamorelin. The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed several peptides in 2022 and 2023. The agency placed tesamorelin on the Category 2 list of bulk drug substances, meaning it may be compounded under Section 503A only when a patient has a documented clinical need that cannot be met by commercially available Egrifta. [3]

This is a meaningful restriction. Under 21 U.S.C. § 503A, a 503A pharmacy (a traditional compounding pharmacy filling patient-specific prescriptions) must demonstrate that the commercially available product is not clinically suitable for that specific patient before using a bulk tesamorelin active pharmaceutical ingredient. 503B outsourcing facilities face an even higher bar and cannot produce office-stock tesamorelin without explicit FDA authorization.

The FDA's guidance document on bulk drug substances states: "A drug product may be compounded under section 503A... Only if the bulk drug substance is... Not a component of a drug product that is the subject of an approved application." [4] Tesamorelin is precisely such a component, so the Category 2 classification reflects that added scrutiny.

Kentucky State Law: What Applies Locally

Kentucky does not independently schedule tesamorelin. A search of KRS Chapter 218A (the Kentucky Controlled Substances Act) returns no listing for tesamorelin or GRF analogues. [5] That means no additional Kentucky-specific Schedule classification restricts access beyond the federal prescription requirement.

Kentucky Board of Pharmacy Rules on Compounding

The Kentucky Board of Pharmacy (KBPhA) regulates compounding pharmacies operating within the state under 201 KAR 2:100 and adopts USP <795> (non-sterile) and USP <797> (sterile) standards. Tesamorelin is a sterile injectable, so any Kentucky-licensed 503A pharmacy filling a compounded tesamorelin prescription must comply with USP <797> clean-room and beyond-use dating requirements. [6]

Out-of-state 503B outsourcing facilities shipping compounded tesamorelin into Kentucky must register with the KBPhA and comply with the state's non-resident pharmacy permit requirements under KRS 315.0351. Patients should verify that any online or mail-order pharmacy dispensing tesamorelin holds a valid KBPhA permit.

Kentucky Medical Practice Act and Off-Label Prescribing

Physicians in Kentucky are governed by KRS Chapter 311 and the Kentucky Board of Medical Licensure (KBML). Off-label prescribing is not prohibited under Kentucky law. The KBML has not issued a specific policy restricting tesamorelin prescriptions to HIV-related indications only, which means a licensed Kentucky prescriber who judges tesamorelin clinically appropriate for another condition (for example, growth hormone deficiency in an HIV-negative patient) may write that prescription within the scope of their professional judgment. The prescriber bears the clinical and medicolegal responsibility for that decision.

Nurse practitioners and physician assistants licensed in Kentucky may also prescribe Schedule II through V controlled substances and non-controlled prescription drugs within their collaborative or supervisory agreements under KRS 314.011 and KRS 311.840.

Who Can Legally Prescribe Tesamorelin in Kentucky

Any of the following providers holding an active Kentucky license may legally prescribe Egrifta or compounded tesamorelin:

• Medical doctors (MD) licensed by the KBML
• Doctors of osteopathic medicine (DO) licensed by the KBML
• Advanced practice registered nurses (APRN) with prescriptive authority from the Kentucky Board of Nursing
• Physician assistants (PA) operating under a supervision agreement with a licensed Kentucky physician

Telehealth providers must also hold an active Kentucky license. Kentucky joined the Interstate Medical Licensure Compact (IMLC), so physicians licensed in a compact state may obtain expedited Kentucky licensure. [7] However, holding a license in another compact state alone does not authorize prescribing to Kentucky patients; an actual Kentucky license is still required.

What the Prescription Must Include

Under 902 KAR 55:110 and federal prescription requirements, a valid tesamorelin prescription must include:

• Patient's full name and address
• Date of issuance
• Drug name, strength, and quantity
• Directions for use (dosing schedule)
• Prescriber's name, address, DEA number (if applicable), and signature
• Number of refills authorized

Because tesamorelin is not a controlled substance, a DEA number is not legally mandated on the prescription. However, most pharmacy management systems require it as a field, and many prescribers include it as standard practice.

Accessing Egrifta (Tesamorelin) in Kentucky

Brand-Name Egrifta Through a Kentucky Pharmacy

Brand Egrifta SV (2 mg/vial, subcutaneous injection once daily) is commercially available and can be dispensed by any Kentucky-licensed retail or specialty pharmacy with a valid prescription. Specialty pharmacies that handle biologic and peptide therapies, such as Shields Health Solutions or local hospital-based specialty pharmacies, are common dispensing points.

Aeterna Zentaris, the manufacturer, operates a patient assistance program (Egrifta SV Access Program) for patients who meet income criteria. The program can reduce out-of-pocket costs significantly below the ~$10,000/month list price.

Compounded Tesamorelin: A Narrower Path

Given the Category 2 Bulks List placement, obtaining compounded tesamorelin legally in Kentucky requires a prescriber to document that brand Egrifta is clinically unsuitable for the specific patient. Reasons a prescriber might legitimately document include:

• A documented allergy to an excipient in the commercial formulation
• A need for a concentration or delivery format not commercially available
• A medically substantiated access barrier (not cost alone, per FDA guidance)

The prescriber's clinical note should explicitly record the reason. Without it, a Kentucky 503A pharmacy risks a KBPhA compliance action, and the prescriber risks a KBML inquiry.

The HealthRX prescriber framework for compounded tesamorelin in Kentucky uses three documentation checkpoints before a prescription is sent to a 503A pharmacy: (1) confirmation that commercial Egrifta is not clinically appropriate with a specific, patient-centered rationale; (2) verification that the 503A pharmacy holds a valid KBPhA permit and meets USP <797> standards; and (3) a written informed-consent note addressing the off-label or compounded nature of the therapy and the associated evidence limitations.

Telehealth Prescribing for Kentucky Patients

Telehealth has expanded access to specialized endocrine care across rural Kentucky. A Kentucky-licensed telehealth provider can evaluate a patient remotely, order IGF-1 and other relevant labs, and write a tesamorelin prescription without an in-person visit, provided the clinical evaluation meets standard-of-care documentation requirements.

The American Association of Clinical Endocrinology (AACE) position on growth-hormone-axis disorders emphasizes that diagnosis should rely on validated biochemical testing and clinical correlation, not symptom checklists alone. [8] A telehealth encounter that includes chart review, symptom history, and laboratory results generally satisfies that standard.

Clinical Evidence Behind Tesamorelin

Understanding the evidence helps patients and prescribers assess the benefit-to-risk ratio before initiating therapy, regardless of the legal pathway used to obtain the drug.

HIV-Associated Lipodystrophy: The Core Approved Indication

The key Phase 3 trials supporting FDA approval enrolled HIV-infected adults on stable antiretroviral therapy. In the combined LIPO-010 and LIPO-011 trials (N=816 total across both studies), tesamorelin 2 mg/day subcutaneously reduced visceral adipose tissue (VAT) by approximately 15 to 18% from baseline compared with 1 to 2% for placebo at 26 weeks, as measured by CT scan. [9] The effect was statistically significant (P<0.001) and clinically meaningful given the cardiometabolic risks associated with excess visceral fat in this population.

The FDA label specifies that treatment effect on VAT should be assessed at 26 weeks. Patients who do not respond should discontinue therapy.

Off-Label Use in Non-HIV Populations

Tesamorelin's mechanism, stimulating the pituitary to release endogenous growth hormone through GRF receptor agonism, has generated interest for non-HIV conditions including adult growth hormone deficiency (aGHD) and age-related somatopause. A randomized trial by Stanley et al. (N=61, NEJM 2014) found that tesamorelin reduced VAT and improved cognitive function in older adults without HIV, though this population is not covered by the current FDA label. [10]

The Endocrine Society's 2011 Clinical Practice Guideline on growth hormone deficiency in adults states: "We recommend confirming the diagnosis of GHD with a GH stimulation test in most patients before starting treatment." [11] This recommendation applies even when considering tesamorelin off-label. A Kentucky prescriber treating non-HIV patients with tesamorelin should document GH stimulation testing results or clearly explain why an alternative diagnostic approach was used.

Safety Profile Relevant to Prescribing Decisions

The most clinically significant adverse effects reported in the key trials include:

• Fluid retention (peripheral edema, arthralgias) in 5 to 10% of patients
• Injection-site reactions in approximately 25% of patients
• Glucose intolerance: tesamorelin can worsen insulin resistance; HbA1c monitoring is recommended at baseline and periodically
• Potential concern for IGF-1 elevation and theoretical neoplasia risk (no causal link established in trial data, but FDA labeling carries a precaution)

Tesamorelin is contraindicated in patients with active malignancy, during pregnancy, and in those with disruption of the hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, head irradiation, or head trauma. [1]

Regulatory Red Flags: What to Avoid

Patients searching for tesamorelin online will encounter vendors offering "research-grade" tesamorelin powder or pre-mixed solutions without a prescription. These products sit outside the legal framework in multiple respects:

First, dispensing tesamorelin without a valid prescription violates 21 U.S.C. § 353(b), which requires a prescription for drugs that are not safe for use without medical supervision. Second, research-chemical vendors are not licensed pharmacies and do not operate under cGMP, USP <797>, or any quality standard. Third, Kentucky law under KRS 218A.1411 and KRS 315.121 prohibits dispensing prescription drugs without a valid prescription; violations may constitute a Class D or Class C felony depending on quantity and intent.

The FDA has issued multiple warning letters to online peptide vendors. The agency's position, confirmed in a 2023 import alert, is that unapproved peptide drug products from unregistered foreign manufacturers are subject to refusal of admission at the U.S. Border. [12]

Practical Steps for Kentucky Patients

Getting tesamorelin legally in Kentucky is a three-step process.

Step 1: Find a qualified Kentucky prescriber. An endocrinologist, infectious disease specialist, or internist familiar with GH-axis disorders is the appropriate starting point. Telehealth platforms staffed by Kentucky-licensed providers offer an accessible alternative for patients in underserved regions of the state.

Step 2: Complete a proper clinical evaluation. Expect lab work including fasting glucose, HbA1c, IGF-1, and, for non-HIV indications, a GH stimulation test. A prescriber skipping labs entirely should be viewed with caution.

Step 3: Fill through a licensed pharmacy. For brand Egrifta, any Kentucky-licensed specialty pharmacy will do. For compounded tesamorelin, confirm the pharmacy holds a KBPhA permit, meets USP <797> sterile compounding standards, and that your prescriber has documented clinical necessity.